FDA approves Guardant's liquid biopsy NGS test

By LabPulse.com staff writers

August 7, 2020 -- The U.S. Food and Drug Administration (FDA) has approved the first liquid biopsy companion diagnostic (CDx) that also uses next-generation sequencing (NGS) to identify patients with specific types of EGFR mutations in a form of metastatic non-small cell lung cancer (NSCLC).

Guardant Health's Guardant360 CDx assay uses a blood sample to provide healthcare professionals with genetic information about the patient's tumor and also large-panel genetic sequencing, known as high-throughput tumor profiling, to detect mutations in 55 tumor genes, rather than one gene at a time.

Patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to faster treatment and more insight into possible resistance mechanisms, the FDA said in a release.

The FDA's approval is specific to the test's use in identifying EGFR mutations in patients who will benefit from treatment with Tagrisso (osimertinib), an FDA-approved therapy for a form of metastatic NSCLC. If the specific NSCLC mutations associated with the FDA's approval are not detected in the blood, a tumor biopsy should be performed to determine if the NSCLC mutations are present, the agency said.

Thrive rakes in $257M to advance multicancer liquid biopsy
Cambridge, MA-based startup Thrive Earlier Detection has raised $257 million in a new round of financing, which the company plans to use to advance...
Cancer research groups partner for liquid biopsy trial
The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy...
Insurance coverage of liquid biopsies for cancer surges
An increasing number of insurance policies are covering liquid biopsies for cancer, according to a study published in the July 2020 issue of the Journal...
Seoul researchers tout Guardant360 clinical results
South Korean researchers highlighted clinical results from a study that used precision oncology company Guardant Health's Guardant360 test in patients...
Survey: Molecular testing greatly underused in lung cancer patients
Molecular testing is greatly underused in patients with non-small cell lung cancer for a variety of reasons, including cost, concerns about quality, turnaround...

Copyright © 2020 LabPulse.com

Last Updated np 8/7/2020 5:18:48 PM